Should I buy or sell STAAR Surgical stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" STAA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STAA, but not buy additional shares or sell existing shares. View STAA analyst ratings or view top-rated stocks .

What is STAAR Surgical's stock price target for 2024?

10 analysts have issued twelve-month price objectives for STAAR Surgical's shares. Their STAA share price targets range from $33.00 to $57.00. On average, they expect the company's share price to reach $46.38 in the next year. This suggests a possible upside of 0.6% from the stock's current price. View analysts price targets for STAA or view top-rated stocks among Wall Street analysts .

How have STAA shares performed in 2024?

STAAR Surgical's stock was trading at $31.21 on January 1st, 2024. Since then, STAA shares have increased by 47.7% and is now trading at $46.09. View the best growth stocks for 2024 here .

When is STAAR Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our STAA earnings forecast .

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) posted its earnings results on Monday, February, 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.01. The medical instruments supplier had revenue of $76.27 million for the quarter, compared to analysts' expectations of $75.94 million. STAAR Surgical had a trailing twelve-month return on equity of 8.73% and a net margin of 6.62%. The company's quarterly revenue was up 19.1% compared to the same quarter last year. During the same period last year, the firm earned $0.04 EPS.

What ETFs hold STAAR Surgical's stock?

ETFs with the largest weight of STAAR Surgical (NASDAQ:STAA) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , Invesco S&P SmallCap Health Care ETF (PSCH) , ROBO Global Healthcare Technology and Innovation ETF (HTEC) , Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Janus Henderson US Sustainable Equity ETF (SSPX) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical updated its FY 2024 earnings guidance on Wednesday, April, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.0 million-$340.0 million, compared to the consensus revenue estimate of $337.2 million.

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com . Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA) , NVIDIA (NVDA) , PayPal (PYPL) , Walt Disney (DIS) , CrowdStrike (CRWD) , DocuSign (DOCU) , Shopify (SHOP) , Trade Desk (TTD) , Teladoc Health (TDOC) and Roku (ROKU) .

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by many different retail and institutional investors. Top institutional investors include APEIRON CAPITAL Ltd (0.72%), State of Alaska Department of Revenue (0.06%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Aimee S Weisner, Broadwood Partners, LP, Caren L Mason , Elizabeth Yeu Lin, Graydon C Hansen , Hans-Martin Blickensdoerfer , James E Francese , Keith Holliday , Patrick F Williams and Samuel J Gesten . View institutional ownership trends .

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does STAAR Surgical have any subsidiaries?

The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD. Read More

NASDAQ:STAA

STAAR Surgical (STAA) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free STAA Stock Alerts

$46.39

-0.38 (-0.81%)

(As of 04:38 PM ET)

Compare

Today's Range: $46.00
▼
$47.33
50-Day Range: $29.49
▼
$52.25
52-Week Range: $26.66
▼
$73.13

Volume: 396,851 shs
Average Volume: 764,257 shs
Market Capitalization: $2.27 billion

P/E Ratio: 107.88
Dividend Yield: N/A
Price Target: $46.38

Get STAAR Surgical alerts:

STAAR Surgical MarketRank™ Stock Analysis

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 0.6% Upside
$46.38 Price Target
Short Interest: Bearish
10.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.44
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$66,692 Bought Last Quarter
Proj. Earnings Growth: 1,600.00%
From $0.03 to $0.51 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.33 out of 5 stars

Medical Sector

118th out of 918 stocks

Ophthalmic Goods Industry

1st out of 7 stocks

2.2

Analyst's Opinion

Consensus Rating
STAAR Surgical has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 4 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
STAAR Surgical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
10.78% of the outstanding shares of STAAR Surgical have been sold short.
Short Interest Ratio / Days to Cover
STAAR Surgical has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in STAAR Surgical has recently decreased by 2.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
STAAR Surgical does not currently pay a dividend.
Dividend Growth
STAAR Surgical does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
STAAR Surgical has received a 58.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Intraocular lenses" product. See details.
Environmental Sustainability
The Environmental Impact score for STAAR Surgical is -0.73.

2.5

News and Social Media Coverage

News Sentiment
STAAR Surgical has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for STAAR Surgical this week, compared to 4 articles on an average week.
Search Interest
29 people have searched for STAA on MarketBeat in the last 30 days. This is an increase of 383% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added STAAR Surgical to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, STAAR Surgical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $66,692.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.10% of the stock of STAAR Surgical is held by insiders.
Percentage Held by Institutions
96.70% of the stock of STAAR Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for STAAR Surgical are expected to grow by 1,600.00% in the coming year, from $0.03 to $0.51 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of STAAR Surgical is 107.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of STAAR Surgical is 107.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.50.
Price to Book Value per Share Ratio
STAAR Surgical has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About STAAR Surgical Stock (NASDAQ:STAA)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STAA Stock News Headlines

April 16, 2024 | marketbeat.com

Star Surgical Shines as U.S. Outlook Improves for 2024

STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).

April 16, 2024 | marketbeat.com

Star Surgical Shines as U.S. Outlook Improves for 2024

STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 17, 2024 | msn.com

STAAR Surgical (STAA) Price Target Increased by 10.42% to 49.24

April 13, 2024 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) PT Raised to $53.00 at Mizuho

April 9, 2024 | americanbankingnews.com

STAAR Surgical (NASDAQ:STAA) PT Raised to $46.00

April 6, 2024 | markets.businessinsider.com

Staar Surgical Holds Promise Amid Strong Q1 Performance, Yet Cautious Outlook Justifies Hold Rating

April 5, 2024 | morningstar.com

Staar Surgical Co STAA

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 5, 2024 | seekingalpha.com

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

April 4, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Schrodinger (SDGR)

April 4, 2024 | benzinga.com

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

April 4, 2024 | marketwatch.com

STAAR Surgical Shares Rise 15% on Preliminary 1Q Sales Figures

April 4, 2024 | msn.com

Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive?

April 4, 2024 | markets.businessinsider.com

In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical

April 4, 2024 | businesswire.com

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

April 2, 2024 | businesswire.com

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

March 28, 2024 | uk.finance.yahoo.com

Global Intraocular Lens Market Expected to Reach USD 9.82 Billion by 2034

March 19, 2024 | finance.yahoo.com

The past three years for STAAR Surgical (NASDAQ:STAA) investors has not been profitable

March 18, 2024 | finance.yahoo.com

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

March 16, 2024 | finance.yahoo.com

STAA Apr 2024 30.000 call

March 16, 2024 | finance.yahoo.com

STAA Apr 2024 35.000 put

March 15, 2024 | finance.yahoo.com

Lateral Flow Assays Market is Expected to Reach $16.8 billion | MarketsandMarkets™

March 11, 2024 | marketwatch.com

Staar Surgical Shares Rises 8.4% After Stifel Upgrade

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Staar Surgical Amidst Growth Potential and Market Headwinds

March 6, 2024 | businesswire.com

STAAR Surgical to Participate in Two Upcoming Investor Conferences

February 28, 2024 | finance.yahoo.com

STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Call Transcript

See More Headlines

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Ophthalmic goods
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:STAA
CUSIP: 85231230
CIK: 718937
Web: www.staar.com
Phone: (626) 303-7902
Fax: 626-303-2962
Employees: 1,115
Year Founded: 1982

Price Target and Rating

Average Stock Price Target: $46.38
High Stock Price Target: $57.00
Low Stock Price Target: $33.00
Potential Upside/Downside: -0.8%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.43
Trailing P/E Ratio: 108.77
Forward P/E Ratio: 1,559.00
P/E Growth: N/A
Net Income: $21.35 million
Net Margins: 6.62%
Pretax Margin: 10.45%
Return on Equity: 8.73%
Return on Assets: 6.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.62
Quick Ratio: 5.08

Sales & Book Value

Annual Sales: $322.42 million
Price / Sales: 7.09
Cash Flow: $0.74 per share
Price / Cash Flow: 63.31
Book Value: $7.91 per share
Price / Book: 5.91

Miscellaneous

Outstanding Shares: 48,870,000
Free Float: 48,328,000
Market Cap: $2.29 billion
Optionable: Optionable
Beta: 0.86

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Thomas G. Frinzi (Age 68)
President, CEO & Chairman
Comp: $94.48k
Mr. Patrick F. Williams (Age 51)
Chief Financial Officer
Comp: $959.99k
Dr. Keith Holliday Ph.D. (Age 61)
Chief Technology Officer
Comp: $829.09k
Mr. James Francese (Age 60)
Senior Vice President of Commercial Operations - North America & APAC
Comp: $755.65k
Dr. Scott D. Barnes M.D. (Age 62)
Chief Medical Officer
Comp: $828.3k
Mr. Warren Foust (Age 48)
Chief Operating Officer
Mr. Brian Moore
Vice President of Investor Relations & Corporate Development
Mr. Samuel J. Gesten (Age 62)
Chief Legal Officer & Corporate Secretary
Comp: $658.25k
Dr. Magda Michna Ph.D.
Chief Clinical, Regulatory & Medical Affairs Officer
Mr. Robert Studholme (Age 71)
Senior Vice President of Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STAA Stock Analysis - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" STAA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STAA, but not buy additional shares or sell existing shares.
View STAA analyst ratings or view top-rated stocks.
What is STAAR Surgical's stock price target for 2024?: 10 analysts have issued twelve-month price objectives for STAAR Surgical's shares. Their STAA share price targets range from $33.00 to $57.00. On average, they expect the company's share price to reach $46.38 in the next year. This suggests a possible upside of 0.6% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.
How have STAA shares performed in 2024?: STAAR Surgical's stock was trading at $31.21 on January 1st, 2024. Since then, STAA shares have increased by 47.7% and is now trading at $46.09.
View the best growth stocks for 2024 here.
When is STAAR Surgical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our STAA earnings forecast.
How were STAAR Surgical's earnings last quarter?: STAAR Surgical (NASDAQ:STAA) posted its earnings results on Monday, February, 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.01. The medical instruments supplier had revenue of $76.27 million for the quarter, compared to analysts' expectations of $75.94 million. STAAR Surgical had a trailing twelve-month return on equity of 8.73% and a net margin of 6.62%. The company's quarterly revenue was up 19.1% compared to the same quarter last year. During the same period last year, the firm earned $0.04 EPS.
What ETFs hold STAAR Surgical's stock?: ETFs with the largest weight of STAAR Surgical (NASDAQ:STAA) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Janus Henderson US Sustainable Equity ETF (SSPX).iShares U.S. Medical Devices ETF (IHI).

What guidance has STAAR Surgical issued on next quarter's earnings?: STAAR Surgical updated its FY 2024 earnings guidance on Wednesday, April, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $340.0 million-$340.0 million, compared to the consensus revenue estimate of $337.2 million.
What is Caren Mason's approval rating as STAAR Surgical's CEO?: 6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.
What other stocks do shareholders of STAAR Surgical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).
Who are STAAR Surgical's major shareholders?: STAAR Surgical's stock is owned by many different retail and institutional investors. Top institutional investors include APEIRON CAPITAL Ltd (0.72%), State of Alaska Department of Revenue (0.06%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Aimee S Weisner, Broadwood Partners, LP, Caren L Mason, Elizabeth Yeu Lin, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends.
How do I buy shares of STAAR Surgical?: Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does STAAR Surgical have any subsidiaries?: The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More

This page (NASDAQ:STAA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial